4.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - Yahoo! Finance Canada
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Aggressive Growth Stocks - Newser
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
CAMP Stock Analysis: CAMP4 Therapeutics biotech review at 4.47 small daily gain - Newser
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress - Investing.com
CAMP PE Ratio & Valuation, Is CAMP Overvalued - Intellectia AI
Aug Swings: Should value investors consider Camp4 Therapeutics Corporation2026 Earnings Surprises & Daily Entry Point Alerts - baoquankhu1.vn
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks
CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart
CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com Australia
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation By Investing.com - Investing.com South Africa
CAMP4 Therapeutics appoints Michael MacLean to board of directors - investing.com
CAMP4 Therapeutics appoints Michael MacLean to board of directors By Investing.com - Investing.com UK
Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union
Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial - Stock Titan
New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan
If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan
Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan
EVTL Technical Analysis & Price Forecast - Intellectia AI
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):